Calgary, AB — December 23, 2025 — Leads & Copy — Elad Bibi-Aviv, CEO of Seegnal Inc. (TSXV: SEGN), a global SaaS leader providing clinical division support solutions for detecting and resolving drug-related problems, has provided an update to investors.
In a recent message, Bibi-Aviv extended warm holiday greetings and expressed gratitude for investors’ continued support. He officially began his tenure as CEO on December 16, 2025.
Bibi-Aviv emphasized the need for safer and more consistent healthcare outcomes amidst rising complexity and capacity constraints. He noted a consistent message emerging from clinicians, health-system leaders, payers/insurers, partners, and team members.
Bibi-Aviv highlighted his experience in building and leading healthcare technology initiatives focused on turning complex care decisions into measurable outcomes. He joined Seegnal to develop the Intelligence Layer of Prescriptions and bring governance and trust to prescribing at scale.
Seegnal’s platform analyzes over 400,000 prescriptions daily and has analyzed over 174 million prescriptions in total. Over 20,000 clinicians currently use the platform, based on Seegnal’s internal client information.
Bibi-Aviv outlined his vision to establish Seegnal as the global Prescription Intelligence Platform, ensuring safer and more consistent prescription decisions. He envisions Seegnal as a Palantir-like intelligence and governance layer for prescriptions.
Seegnal’s platform offers two key benefits:
- For clinicians: AI-supported guidance embedded directly in workflow to empower better prescribing in real time.
- For healthcare organizations and insurers: System-wide visibility, aligned policies, and continuous improvement to enable prescription governance at scale.
Seegnal is building the Intelligence Layer of Prescriptions, a workflow-native, human-led, AI-enhanced platform that combines real-time decision support with an enterprise governance layer.
The company’s near-term priorities include:
- Accelerating commercial expansion, starting in the U.S.
- Prioritizing explainability, clinical trust, and workflow fit to keep Seegnal human-led and AI-enhanced.
- Deepening the measurement and communication of safety, adoption, and ROI across deployments.
- Scaling enterprise readiness through integration excellence, security, reliability, and performance.
- Building the governance layer with dashboards, controls, and continuous optimization for organizations and insurers.
Seegnal aims to solve the problem of Adverse Drug Effects (ADEs) by implementing a new Patient-Centric Standard. Its SaaS technology integrates patient-specific data at the point-of-care, reducing alert load for clinicians.
Seegnal eHealth is marketing its platform in Israel, the United Arab Emirates, the United Kingdom, the United States, and Poland. It is currently a “standard of care” system for over 10,000 clinicians in Israel.
Elad Bibi-Aviv can be reached at elad.bibiaviv@seegnal.com or +972 52 533 0856 / +1 (929) 248-4652.
Source: Seegnal Inc.
